Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.
This report contains a comprehensive listing of 670 monoclonal antibody deals announced since 2019 including financial terms where available, along with links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of monoclonal antibody deals from 2019 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals. The initial chapters of this report offer a structured introduction to monoclonal antibody dealmaking. They cover the introduction to the report, recent trends, notable deals, and a listing of the top 25 active companies. Furthermore, these chapters provide detailed reviews of deals organized by technology type and include public domain contract documents.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
2.7.1 Monoclonal antibody deals headline values
2.7.2 Monoclonal antibody deal upfront payments
2.7.3 Monoclonal antibody deal milestone payments
2.7.4 Monoclonal antibody royalty rates
Chapter 3 - Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value
Chapter 4 - Most active monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody deals company profiles
Chapter 5 - Monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory
Chapter 6 - Monoclonal antibody dealmaking by technology type
Deal directory
Deal directory - Monoclonal antibody deals by company A-Z
Deal directory - Monoclonal antibody deals by deal type
Deal directory - Monoclonal antibody deals by therapy area
Deal type definitions
Companies Featured (Partial)
- Aespire Bio
- Aggrecept
- Aligos Therapeutics
- Alladapt Immunotherapeutics
- AltaThera Pharmaceuticals
- Ancora Heart
- Anokion
- Arcellx
- Aruvant Sciences
- Athira Pharma
- Avacta Life Sciences
- Axovant Gene Therapies
- Bioclin Therapeutics
- BioNTech
- Cardiff Oncology
- Cassava Sciences
- Cidara Therapeutics
- CytoDyn
- Dicerna Pharmaceuticals
- Edgewise Therapeutics
- G1 Therapeutics
- Gero Therapeutics
- HarbourBioMed
- ImaginAb
- Karuna Therapeutics
- Kezar Life Sciences
- Microbix Biosystems
- MiNA Therapeutics
- Nkarta Therapeutics
- Nurix Therapeutics
- Oncorus
- Optinose
- OSE Immunotherapeutics
- Protagonist Therapeutics
- PsychoGenics
- Renovacor
- Reviva Pharmaceuticals
- Sigilon Therapeutics
- Solid Biosciences
- Surrozen
- Synairgen
- Talis Biomedical
- Tenaya Therapeutics
- Terns Pharmaceuticals
- Twist Bioscience
- UroGen Pharma
- Vaxart
- Vertex Pharmaceuticals
- Xenetic Biosciences
- Zentalis Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/iyrcc0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
